Where does compounded semaglutide API come from? FDA import records by country
Where does compounded semaglutide API come from?
FDA’s import records show where semaglutide API offered for U.S. import was made, not which pharmacy used it. The Green List of FDA’s Import Alert 66-80 (published Oct 9, 2026) has 10 entries naming semaglutide: China (7), Belgium (1), Denmark (1) and Portugal (1), with the firm names redacted by FDA. FDA’s import refusal files (Jan 1, 2002 to Oct 30, 2026) list 11 refused lines with a semaglutide API or powder product code, from China (11), among 501 refused semaglutide lines in all.
Records read Nov 15, 2026. Import Alert 66-80 is FDA’s import alert for GLP-1 bulk drug substances; its own text says that during the shortages, “APIs used to compound GLP-1 drug products were supplied by various API manufacturers located around the world, including China, India, and Europe.”
Green List entries naming semaglutide, by country
| CHINA | 7 |
| BELGIUM | 1 |
| DENMARK | 1 |
| PORTUGAL | 1 |
| Product codes and drugs listed | |||
|---|---|---|---|
| 1 | Redacted by FDA | BELGIUM | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]75 Exenatide (Anti-Diabetic) |
| 4 | Redacted by FDA | CHINA | 56F[][]99 Peptide N.E.C. (Antibiotics) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) |
| 5 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 7 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 8 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 10 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 12 | Redacted by FDA | CHINA | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 13 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 15 | Redacted by FDA | DENMARK | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) |
| 20 | Redacted by FDA | PORTUGAL | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]77 Orforglipron SDD (Anti-Diabetic) |
Refused semaglutide API or powder lines, by country
A line counts here when its FDA product code is one Import Alert 66-80 lists as a semaglutide API or powder form (process indicator codes the alert describes as “Active Pharm Ingred/Chems for Further Manuf”, “Active Pharm Ingred/Chems for Rx Compounding”, “NonSterile Powder” or “Sterile Powder”).
| China | 11 |
| FDA refusal charges | Shipment ID | |||||
|---|---|---|---|---|---|---|
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/4 |
| May 19, 2026 | NANJING HANXIN INTERNATIONAL | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 1FX-1577805-2/10003/1 |
| May 14, 2026 | Hybio Pharmaceutical (Wuhan) Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 8NP-0144593-5/10002/1 |
| Aug 6, 2025 | Harbin Jixianglong Biotech Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | H77-0229191-2/13/1 |
| May 1, 2025 | Hangzhou ThinHeal Pharma-Tech Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2501606-4/12/1 |
| Oct 28, 2024 | Fujian Genohope Biotech Ltd | China | 61PCS72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Further Manuf | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-5719160-1/11/1 |
| Jan 25, 2024 | Qingdao Biopeptek Co., Ltd. | China | 61PCR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | AEK-3647198-3/11/1 |
| Dec 6, 2023 | Qingdao Biopeptek Co., Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3571990-3/11/1 |
| Oct 11, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PDT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 906-0395480-4/11/1 |
| Sep 27, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PDT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 8V8-0000195-1/11/2 |
| Sep 7, 2023 | Zhejiang Peptites Biotech Co.,Ltd. | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 8GX-8000731-3/11/1 |
All refused semaglutide lines, by form
490 of the 501 refused semaglutide lines carry a product code that Import Alert 66-80 does not list as an API or powder form. The form column uses the alert’s own wording where the alert lists the code.
| Code not listed on Import Alert 66-80 | 490 |
| Active Pharm Ingred/Chems for Rx Compounding | 8 |
| NonSterile Powder | 2 |
| Active Pharm Ingred/Chems for Further Manuf | 1 |
| Canada | 208 |
| Denmark | 149 |
| United States | 26 |
| China | 19 |
| Colombia | 17 |
| United Kingdom | 15 |
| India | 14 |
| Mexico | 11 |
| Brazil | 9 |
| Bangladesh | 5 |
| Germany | 4 |
| Singapore | 4 |
| France | 3 |
| Hong Kong | 2 |
| Israel | 2 |
| Japan | 2 |
| Nigeria | 2 |
| Albania | 1 |
| Bulgaria | 1 |
| Egypt | 1 |
| Greece | 1 |
| Honduras | 1 |
| Indonesia | 1 |
| Italy | 1 |
| Philippines | 1 |
| Turkey | 1 |
What these records do not show
FDA prints a redaction in place of every firm name on the Import Alert 66-80 Green List, so the list shows countries and drugs, not companies. Import refusals record shipment lines FDA refused, not shipments it admitted, and they do not say which pharmacy or other buyer the API was meant for. Neither record says which supplier a given pharmacy uses.
Firms named on refused lines: Firms on GLP-1 import records.
Common questions
Does FDA publish which companies are on the GLP-1 API Green List?
The Import Alert 66-80 page lists 21 Green List entries with country and product codes, and prints a redaction in place of each firm name (read Nov 15, 2026).
Which countries are on the Green List for semaglutide?
China (7), Belgium (1), Denmark (1) and Portugal (1), as of the alert published Oct 9, 2026.
What does a refusal record show?
That FDA refused admission of one shipment line, with the charges FDA cited. It is not a test result unless the line is marked for FDA sample analysis.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.